{"doc_id": "32702299", "type of study": "Therapy", "title": "", "abstract": "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.\nThis is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study.\nThis randomised, double-blind, placebo-controlled, phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan, China.\nHealthy adults aged 18 years or older, who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-free, were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1\u2008\u00d7\u20081011 viral particles per mL or 5\u2008\u00d7\u20081010 viral particles per mL, or placebo.\nInvestigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm.\nThe randomisation list (block size 4) was generated by an independent statistician.\nParticipants, investigators, and staff undertaking laboratory analyses were masked to group allocation.\nThe primary endpoints for immunogenicity were the geometric mean titres (GMTs) of specific ELISA antibody responses to the receptor binding domain (RBD) and neutralising antibody responses at day 28.\nThe primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days.\nAll recruited participants who received at least one dose were included in the primary and safety analyses.\nThis study is registered with ClinicalTrials.gov, NCT04341389.\n603 volunteers were recruited and screened for eligibility between April 11 and 16, 2020.\n508 eligible participants (50% male; mean age 39\u00b77 years, SD 12\u00b75) consented to participate in the trial and were randomly assigned to receive the vaccine (1\u2008\u00d7\u20081011 viral particles n=253; 5\u2008\u00d7\u20081010 viral particles n=129) or placebo (n=126).\nIn the 1\u2008\u00d7\u20081011 and 5\u2008\u00d7\u20081010 viral particles dose groups, the RBD-specific ELISA antibodies peaked at 656\u00b75 (95% CI 575\u00b72-749\u00b72) and 571\u00b70 (467\u00b76-697\u00b73), with seroconversion rates at 96% (95% CI 93-98) and 97% (92-99), respectively, at day 28.\nBoth doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2, with GMTs of 19\u00b75 (95% CI 16\u00b78-22\u00b77) and 18\u00b73 (14\u00b74-23\u00b73) in participants receiving 1\u2008\u00d7\u20081011 and 5\u2008\u00d7\u20081010 viral particles, respectively.\nSpecific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination were observed in 227 (90%, 95% CI 85-93) of 253 and 113 (88%, 81-92) of 129 participants in the 1\u2008\u00d7\u20081011 and 5\u2008\u00d7\u20081010 viral particles dose groups, respectively.\nSolicited adverse reactions were reported by 183 (72%) of 253 and 96 (74%) of 129 participants in the 1\u2008\u00d7\u20081011 and 5\u2008\u00d7\u20081010 viral particles dose groups, respectively.\nSevere adverse reactions were reported by 24 (9%) participants in the 1\u2008\u00d7\u20081011 viral particles dose group and one (1%) participant in the 5\u2008\u00d7\u20081010 viral particles dose group.\nNo serious adverse reactions were documented.\nThe Ad5-vectored COVID-19 vaccine at 5\u2008\u00d7\u20081010 viral particles is safe, and induced significant immune responses in the majority of recipients after a single immunisation.\nNational Key R&D Programme of China, National Science and Technology Major Project, and CanSino Biologics.\nCopyright \u00a9 2020 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "healthy adults", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 104}, {"term": "Healthy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 7}, {"term": "HIV-negative", "negation": "negated", "UMLS": {}, "start": 49, "end": 61}, {"term": "previous severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection-free", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 152}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older : a randomised , double-blind, placebo-controlled, phase 2 trial .", "Evidence Elements": {"Participant": [{"term": "healthy adults", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 104}], "Intervention": [{"term": "recombinant adenovirus type-5-vectored COVID-19 vaccine", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 86, "has_chemical": [{"text": "recombinant adenovirus", "maps_to": "C1514767:recombinant adenovirus-p53", "start": 0, "end": 22}, {"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 48, "end": 55, "has_count": ["19"]}], "has_relation": "N/A"}], "Outcome": [{"term": "Immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 25}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 ( Ad5 ) -vectored COVID-19 vaccine , aiming to determine an appropriate dose of the candidate vaccine for an efficacy study .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "non-replicating adenovirus type-5 ( Ad5 ) -vectored COVID-19 vaccine", "negation": "affirmed", "UMLS": {}, "start": 109, "end": 177, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 52, "end": 59, "has_count": ["19"]}], "has_relation": "N/A"}, {"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 170, "end": 177, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "immunogenicity", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 82}, {"term": "safety", "negation": "affirmed", "UMLS": {}, "start": 87, "end": 93}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This randomised , double-blind , placebo-controlled , phase 2 trial of the Ad5-vectored COVID-19 vaccine was done in a single centre in Wuhan , China .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Ad5-vectored COVID-19 vaccine", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 104, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 22, "end": 29, "has_count": ["19"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Healthy adults aged 18 years or older , who were HIV-negative and previous severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection-free , were eligible to participate and were randomly assigned to receive the vaccine at a dose of 1 \u00d7 1011 viral particles per mL or 5 \u00d7 1010 viral particles per mL , or placebo .", "Evidence Elements": {"Participant": [{"term": "Healthy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 7}, {"term": "HIV-negative", "negation": "negated", "UMLS": {}, "start": 49, "end": 61}, {"term": "previous severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) infection-free", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 152}], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 226, "end": 233, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Investigators allocated participants at a ratio of 2:1:1 to receive a single injection intramuscularly in the arm .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The randomisation list ( block size 4 ) was generated by an independent statistician .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants , investigators , and staff undertaking laboratory analyses were masked to group allocation .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoints for immunogenicity were the geometric mean titres ( GMTs ) of specific ELISA antibody responses to the receptor binding domain ( RBD ) and neutralising antibody responses at day 28 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "geometric mean titres ( GMTs ) of specific ELISA antibody responses to the receptor binding domain ( RBD )", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 156}, {"term": "neutralising antibody", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 182}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary endpoint for safety evaluation was the incidence of adverse reactions within 14 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "incidence of adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 81}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "All recruited participants who received at least one dose were included in the primary and safety analyses .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This study is registered with ClinicalTrials.gov , NCT04341389 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "603 volunteers were recruited and screened for eligibility between April 11 and 16 , 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "508 eligible participants ( 50 % male ; mean age 39\u00b77 years , SD 12\u00b75 ) consented to participate in the trial and were randomly assigned to receive the vaccine ( 1 \u00d7 1011 viral particles n = 253 ; 5 \u00d7 1010 viral particles n = 129 ) or placebo ( n = 126 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 159, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "In the 1 \u00d7 1011 and 5 \u00d7 1010 viral particles dose groups , the RBD-specific ELISA antibodies peaked at 656\u00b75 ( 95 % CI 575\u00b72-749\u00b72 ) and 571\u00b70 ( 467\u00b76-697\u00b73 ) , with seroconversion rates at 96 % ( 95 % CI 93-98 ) and 97 % ( 92-99 ) , respectively , at day 28 .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "1 \u00d7 1011", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 15, "has_relation": "N/A"}, {"term": "5 \u00d7 1010 viral particles dose", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 49, "has_chemical": [{"text": "viral particles", "maps_to": "C0597177:particles", "start": 9, "end": 24, "has_count": ["1010"]}], "has_relation": "N/A"}], "Outcome": [{"term": "RBD-specific ELISA antibodies", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 92}, {"term": "seroconversion rates", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 186}], "Observation": [{"term": "peaked", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 99}, {"term": "656\u00b75", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 108}, {"term": "571\u00b70 ( 467\u00b76-697\u00b73 )", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 158}, {"term": "96 %", "negation": "affirmed", "UMLS": {}, "start": 190, "end": 194}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "96 %", "Outcome": "seroconversion rates", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Both doses of the vaccine induced significant neutralising antibody responses to live SARS-CoV-2 , with GMTs of 19\u00b75 ( 95 % CI 16\u00b78-22\u00b77 ) and 18\u00b73 ( 14\u00b74-23\u00b73 ) in participants receiving 1 \u00d7 1011 and 5 \u00d7 1010 viral particles , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Both doses of the vaccine", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 25, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 18, "end": 25}], "has_relation": "N/A"}, {"term": "1 \u00d7 1011", "negation": "affirmed", "UMLS": {}, "start": 188, "end": 196, "has_relation": "N/A"}], "Outcome": [{"term": "neutralising antibody responses to live SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 96}, {"term": "GMTs", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 108}], "Observation": [{"term": "significant", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 45}, {"term": "19\u00b75", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 116}, {"term": "18\u00b73 ( 14\u00b74-23\u00b73 )", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 161}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Both doses of the vaccine", "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 18, "end": 25}], "has_relation": "N/A"}, "Observation": "19\u00b75", "Outcome": "GMTs", "Count": ""}, {"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "19\u00b75", "Outcome": "GMTs", "Count": ""}, {"Intervention": {"term": "Both doses of the vaccine", "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 18, "end": 25}], "has_relation": "N/A"}, "Observation": "18\u00b73 ( 14\u00b74-23\u00b73 )", "Outcome": "GMTs", "Count": ""}, {"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "18\u00b73 ( 14\u00b74-23\u00b73 )", "Outcome": "GMTs", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination were observed in 227 ( 90 % , 95 % CI 85-93 ) of 253 and 113 ( 88 % , 81-92 ) of 129 participants in the 1 \u00d7 1011 and 5 \u00d7 1010 viral particles dose groups , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "1 \u00d7 1011", "negation": "affirmed", "UMLS": {}, "start": 185, "end": 193, "has_relation": "N/A"}], "Outcome": [{"term": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 79}], "Observation": [], "Count": [{"term": "227 ( 90 %", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 107}, {"term": ") of 253", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 132}, {"term": "113 ( 88 %", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 147}, {"term": ") of 129 participants", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 177}]}, "Evidence Propositions": [{"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "", "Count": "227 ( 90 %", "Outcome": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination"}, {"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "", "Count": ") of 253", "Outcome": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination"}, {"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "", "Count": "113 ( 88 %", "Outcome": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination"}, {"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "", "Count": ") of 129 participants", "Outcome": "Specific interferon \u03b3 enzyme-linked immunospot assay responses post vaccination"}]}, {"Section": "FINDINGS", "Text": "Solicited adverse reactions were reported by 183 ( 72 % ) of 253 and 96 ( 74 % ) of 129 participants in the 1 \u00d7 1011 and 5 \u00d7 1010 viral particles dose groups , respectively .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "1 \u00d7 1011", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 116, "has_relation": "N/A"}, {"term": "5 \u00d7", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 124, "has_relation": "N/A"}], "Outcome": [{"term": "Solicited adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 27}], "Observation": [], "Count": [{"term": "183 ( 72 % ) of 253", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 64}, {"term": "96 ( 74 % ) of 129 participants", "negation": "affirmed", "UMLS": {}, "start": 69, "end": 100}]}, "Evidence Propositions": [{"Intervention": {"term": "1 \u00d7 1011", "has_relation": "N/A"}, "Observation": "", "Count": "183 ( 72 % ) of 253", "Outcome": "Solicited adverse reactions"}, {"Intervention": {"term": "5 \u00d7", "has_relation": "N/A"}, "Observation": "", "Count": "96 ( 74 % ) of 129 participants", "Outcome": "Solicited adverse reactions"}]}, {"Section": "FINDINGS", "Text": "Severe adverse reactions were reported by 24 ( 9 % ) participants in the 1\u00d71011 viral particles dose group and one ( 1 % ) participant in the 5\u00d7 1010 viral particles dose group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "1\u00d71011 viral particles dose", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 100, "has_chemical": [{"text": "viral particles", "maps_to": "C0597177:particles", "start": 7, "end": 22, "has_count": ["1011"]}], "has_relation": "N/A"}, {"term": "5\u00d7 1010 viral", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 155, "has_relation": "N/A"}], "Outcome": [{"term": "Severe adverse reactions", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 24}], "Observation": [], "Count": [{"term": "24 ( 9 % ) participants", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 65}, {"term": "one ( 1 % ) participant", "negation": "affirmed", "UMLS": {}, "start": 111, "end": 134}]}, "Evidence Propositions": [{"Intervention": {"term": "1\u00d71011 viral particles dose", "has_chemical": [{"text": "viral particles", "maps_to": "C0597177:particles", "start": 7, "end": 22, "has_count": ["1011"]}], "has_relation": "N/A"}, "Observation": "", "Count": "24 ( 9 % ) participants", "Outcome": "Severe adverse reactions"}, {"Intervention": {"term": "5\u00d7 1010 viral", "has_relation": "N/A"}, "Observation": "", "Count": "one ( 1 % ) participant", "Outcome": "Severe adverse reactions"}]}, {"Section": "FINDINGS", "Text": "No serious adverse reactions were documented .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse reactions", "negation": "negated", "UMLS": {}, "start": 3, "end": 28}], "Observation": [], "Count": [{"term": "No", "negation": "negated", "UMLS": {}, "start": 0, "end": 2}]}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "The Ad5-vectored COVID-19 vaccine at 5 \u00d7 1010 viral particles is safe , and induced significant immune responses in the majority of recipients after a single immunisation .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Ad5-vectored COVID-19 vaccine", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 33, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 22, "end": 29, "has_count": ["19"]}], "has_relation": "N/A"}], "Outcome": [{"term": "immune responses", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 112}], "Observation": [{"term": "safe", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 69}, {"term": "significant", "negation": "affirmed", "UMLS": {}, "start": 84, "end": 95}], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "National Key R&D Programme of China , National Science and Technology Major Project , and CanSino Biologics .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}